Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Panitumumab (DB01269)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03751176Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic ColorectalTreatment
NCT03186326Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerTreatment
NCT03584711FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS MutationTreatment
NCT01991873Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal CancerTreatment
NCT02980510Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer PatientsTreatment
NCT02476045Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)Treatment